Description

Developed by Lux Capital, the Lux Bio + Tech Index™ is a secular investment theme that covers companies innovating to further the molecular understanding of the "omics stack" to companies building "operating systems" for the future of drug discovery and ultimately even drug development. Over time these companies have transformed from radical, even heretical, ideas to undeniable technical, scientific, and clinical proof points. The last decade has ushered in an unparalleled understanding of the molecular basis of biology, enabled by emergent tool kits to engineer and perturb biology, ultimately increasing the velocity of discovery. Today, Moore's Law-like cost curves exist along many axes in biotech and have given rise to an era of precise, high fidelity, large scale, highly reproducible, and increasingly automated biological and chemical experimentation and discovery. The modern scientist-entrepreneur not only sits at the wetbench but also has proficiency to deconvolute high dimensional and historically unmanageable data with GPUs, the cloud, and the array of advances from machine learning and deep learning.